These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 22262762)

  • 21. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
    Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
    Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.
    Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
    Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukemic Stem Cell (CD34
    Mohamed MMI; Aref S; Agdar MA; Mabed M; El-Sokkary AMA
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):508-513. PubMed ID: 33931379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The Predict Significance of ALDH Activity to the Relapse of t(8;21) Acute Myeloid Leukemia Patients at Complete Remission].
    Yang L; Dao FT; Wang YZ; Liu YR; Jiang H; Jiang Q; Liu KY; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):43-48. PubMed ID: 33554795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometric analysis of CD34
    Mizuta S; Iwasaki M; Bandai N; Yoshida S; Watanabe A; Takashima H; Ueshimo T; Bandai K; Fujiwara K; Hiranuma N; Koba Y; Kawata T; Tamekane A; Watanabe M
    Cytometry B Clin Cytom; 2024 Jan; 106(1):35-44. PubMed ID: 37933409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Eisenwort G; Sadovnik I; Schwaab J; Jawhar M; Keller A; Stefanzl G; Berger D; Blatt K; Hoermann G; Bilban M; Willmann M; Winding C; Sperr WR; Arock M; Rülicke T; Reiter A; Valent P
    Leukemia; 2019 Nov; 33(11):2673-2684. PubMed ID: 30953030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
    Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
    Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.
    Plesa A; Elhamri M; Clapisson G; Mattei E; Gazzo S; Hequet O; Tigaud I; Michallet M; Dumontet C; Thomas X
    Leuk Lymphoma; 2015 Mar; 56(3):622-9. PubMed ID: 24884314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
    Levis M; Murphy KM; Pham R; Kim KT; Stine A; Li L; McNiece I; Smith BD; Small D
    Blood; 2005 Jul; 106(2):673-80. PubMed ID: 15797998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
    Karantanos T; Jones RJ
    Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.
    Cheung AM; Wan TS; Leung JC; Chan LY; Huang H; Kwong YL; Liang R; Leung AY
    Leukemia; 2007 Jul; 21(7):1423-30. PubMed ID: 17476279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.